



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Diroximel Fumarate

Item No. 29111

CAS Registry No.: 1577222-14-0
Formal Name: (2E)-butenedioic acid, 1-[2-(2,5-dioxo-1-pyrrolidiny)ethyl] 4-methyl ester
Synonym: BIIB098
MF: C₁₁H₁₃NO₆
FW: 255.2
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Diroximel fumarate is supplied as a solid. A stock solution may be made by dissolving the diroximel fumarate in the solvent of choice, which should be purged with an inert gas. Diroximel fumarate is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of diroximel fumarate in these solvents is approximately 10 mg/ml.

Diroximel fumarate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, diroximel fumarate should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Diroximel fumarate has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Diroximel fumarate is a prodrug form of monomethyl fumarate (Item No. 27813).¹ It undergoes esterase cleavage in the gut to release monomethyl fumarate. Formulations containing diroximel fumarate have been used in the treatment of relapsing-remitting multiple sclerosis.

Reference

1. Naismith, R.T., Wolinsky, J.S., Wundes, A., *et al.* Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. *Mult. Scler.* (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/10/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM